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Introduction
Dementia is a clinical syndrome characterized by a pro-
gressive and irreversible cognitive decline, which mainly 
affects the memory, functionality and person’s behaviour, 
producing major personality changes. Alzheimer’s disease 
(AD) is recognized as the most common cause of dementia 
worldwide, accounting for approximately 80% of all demen-
tia cases [1].
Research study has shown that the diagnosis of 
Alzheimer’s disease is defined by the presence of amyloid 
beta (Aβ), neurofibrillary glands (NFTs), neurodegenera-
tion and not by the presence of specific symptomatology [2].
Statistics has shown that women are more affected by 
AD compared with men. In the United States, 2/3 of those 
affected by AD are women [3]. Initially, female longevity 
was considered the main reason of AD. Although, subse-
quent studies proved that the involved mechanisms are 
much more complex and include intrinsic factors related to 
genetic, endocrine, inflammatory, and structural character-
istics of the brain. All these factors have a well-defined role 
in this imbalance. [4].
Brain structural differences
First and foremost, women’s and men’s brains differ 
structurally. In various studies, with the help of MRI, was 
shown that men have larger tonsil and thalamus, while 
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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease of the elderly, being recognized worldwide as the most common cause of dementia. 
However, the harm generated by this disease to women and men is disproportionate, in women the disease is recorded twice as much. Numerous research 
studies have tried to find an answer regarding the causes of this disproportionality. So far, some fundamental differences between macroscopic, microscopic 
and biochemical structures of female vs. male brain have been investigated. First of all, emphasis was placed on macroscopic structural differences. In this 
study, a particular role was attributed to APOE4 gene which was shown to be an increased risk factor of AD in women who possess this allele. Hormonal 
changes in women, such as decreased postmenopausal estrogen, greatly influence disease incidence and prevalence. All these factors tell about the increased 
susceptibility of women to this disease.  However, the definite mechanisms of this disease are incompletely elucidated and further studies are needed.
Conclusions: The identification of pathobiochemical mechanisms based on gender, that influence the incidence and prevalence of Alzheimer’s disease 
is essential. Thus, it could be a target in the development of effective preventive therapeutic strategies from the prodromal phase of the disease. In this 
context, the development of personalized treatment according to gender specifics should be considered in future.
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women have a larger hippocampus [5]. Women’s cerebral 
volume is smaller, but richer in grey matter as compared 
with men’s one, which is larger in size and has bigger vol-
ume of white matter [6]. As well, men have greater inter-
hemispheric connectivity. However, when we talk about 
metabolism, in women the blood flow is more abundant in 
the parietal cortex, and in men it is richer in motor, visual 
cortex, and in cerebellum [7, 8].
Implications of APOE4 gene
APOE gene encodes APOE protein, which binds to lip-
ids, forming lipoproteins. Their role is essential in the cho-
lesterol transport through the blood stream [9]. At least 3 al-
leles of APOE gene are known: APOE2, APOE3 and APOE4 
[10]. ε4 allele of APOE4 gene represents a genetic risk factor 
for sporadic AD with late onset [11]. APOE4 allele was as-
sociated with mitochondrial dysfunction and glucose hypo-
metabolism in the brain [12]. There are major differences 
between female and male APOE4 allele carriers. Women 
who possess E4 allele have a higher genetic risk of AD devel-
oping, which is manifested by a more rapid evolution with 
a more severe cognitive decline, compared with men that 
have the same allele [10, 13]. Concurrently, the female E4 al-
lele carriers are more likely to develop AD because they are 
more susceptible to protein accumulation. This condition 
effects directly beta amyloid aggregation and promotes pro-
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teolytic cleavage that generates toxic fragments in the brain 
[6, 14]. Women are endowed with a larger neural network 
that serves as brain reserve and allows the compensation of 
amyloid deposition, that results in a significantly higher ver-
bal memory [15].
Hormonal imbalance and menopause
AD pathobiochemical changes manifest slowly, progres-
sively and may last for decades. Studies suggest that the in-
creased risk for women to develop the disease between 65 
and 75 years is due to hormonal changes and menopause, 
which begin 15-20 years earlier [16]. Menopause is consid-
ered to be a neuroendocrine transition and ends with repro-
ductive senescence. It presents a set of neurological symp-
toms, and causes estrogen regulation dysfunctions, such as 
thermoregulation, sleep and circadian rhythms, depression 
and impairment of multiple cognitive domains. It has been 
shown that the menopause onset is directly influenced by 
the uncoupling of brain energy metabolism, which in turn 
is mediated by estrogen. Both men and women produce es-
trogen, only that women produce a much higher amount 
of estrogen, which is also called the female hormone. With 
menopause onset, hormone production decreases. On the 
other hand, men continue to produce testosterone – the 
male sex hormone, which when reaches the brain cells, is 
converted into estrogen. In conclusion, at the same age, 
women have less estrogen in the brain compared with men 
[17, 18].
Oestrogen actions in the brain
Oestrogen plays an essential role and has multiple func-
tions in the reproductive, cardiovascular, skeletal, and cen-
tral nervous systems physiology. Oestrogen is vital for pre-
frontal cortex and hippocampus functioning and initiates 
spinogenesis and synaptogenesis [19, 20]. Three physiologi-
cal estrogens are known, including estradiol (E2). During 
menopause, it decreases producing a series of changes in 
cognition, sleep, and mood. Studies have shown that estra-
diol also interacts with cholinergic, dopaminergic and mito-
chondrial functions [21]. Oestrogen has a neuroprotective 
role against dementia, and its dysfunction aggravates the 
neurodegenerative process, especially in women [22, 23]. 
For many years, epidemiological studies have shown that 
the prevalence of Alzheimer’s disease was significantly lower 
in women taking postmenopausal hormone therapy, or the 
disease was milder compared with those who did not [24]. 
However, a case-control study in Finland, conducted be-
tween 1999-2013 and attended by 84739 women diagnosed 
with postmenopausal AD, has shown surprizing results. The 
results of the study demonstrated that long-term systemic 
hormone therapy may be accompanied by an increased risk 
of AD. Only vaginal estradiol presents no risk [25].
Mitochondria
In cellular metabolism, mitochondria play an essential 
role, not only for ATP production, but also in the produc-
tion of reactive oxygen species (ROS) following the dis-
charge of electrons from the respiratory chain [26]. In the 
presence of beta amyloid, mitochondria increase the forma-
tion of reactive oxygen species which on the one hand are 
harmful, but on the other hand act as signalling molecules 
[27]. Mitochondria are an essential source of ROS in cells 
that have high oxidative capacity, such as neurons, skeletal 
muscle cells and cardiomyocytes. Upon prolonged expo-
sure, ROS can produce mutations in mtDNA, which ac-
cumulate over years. Primordial impairment occurs on the 
mitochondrial cells of the brain. However, in mouse experi-
ments, in the mitochondrial cells of the female mouse brain, 
lower oxidative stress was found when compared with the 
male ones [28]. The liver and brain mitochondria of the 
female mouse produce less peroxides than the male ones. 
Nevertheless, ovarectomy reversed this process, equalling 
female/male peroxides production. Estrogen replacement 
therapy produced surprising results, namely the peroxides 
production was smaller in female than in male (F<M). Thus, 
the lack of postmenopausal oestrogen administration may 
be the reason for the increased AD prevalence among wo-
men [29].
Depression prevalence in women
Depression is an important risk factor for developing 
Alzheimer’s disease [30]. The hippocampus represents a 
brain structure composed of dentate gyrus, and hippocam-
pus itself which is composed of three fields – CA1, CA2, 
CA3 and subiculum. It is a structure responsible for learn-
ing and memory, which is affected in AD [31]. Gender and 
sex differences exist and are related mainly to hippocampal 
plasticity and cognition, women being more prone to cogni-
tive decline in Alzheimer’s disease [32]. Numerous studies 
have shown that the increased prevalence of depression in 
women correlates with hormonal changes and is predomi-
nantly manifested during puberty, before menstruation, af-
ter pregnancy and perimenopause. Estrogen administration 
decreases the risk of depression. But why do men who pos-
sess testosterone have lower rates of depression? Research 
has shown that in the male brain there are many receptors 
for estrogen, and through endogenous aromatase, testos-
terone turns into estrogen. Apart from the hormonal im-
plications, the presence of different brain circuits in men is 
suspected [33]. In women with mild cognitive impairment, 
proteins spread earlier and faster through the brain than in 
men’s brain [34, 35].
Conclusions
Gender in Alzheimer’s disease could be a potential risk 
factor, as studies have shown that 2/3 of women are affected 
by this disease. Although, it was initially thought that this 
is due to the female longevity. Later, various research stud-
ies have shown the involvement of several macroscopic and 
biochemical factors in this disproportionality.
The identification of pathobiochemical mechanisms 
based on gender, that influence the incidence and preva-
lence of Alzheimer’s disease is essential. Thus, it could be a 
target in the development of effective preventive therapeutic 
strategies from the prodromal phase of the disease. In this 
context, the development of personalized treatment accord-
ing to gender specifics should be considered in future.
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